Document is current

Article History

Received: 15 January 2021

Accepted: 13 January 2022

First Online: 2 February 2022

Competing interests

: A. Lee reports support from the US Food and Drug Administration, grants from Santen, Regeneron, Carl Zeiss Meditec, and Novartis, personal fees from Genentech, Topcon, and Verana Health, outside of the submitted work; This article does not reflect the opinions of the Food and Drug Administration. P. K. Bhatraju reports support from the National Institute of Health (NIH). S. Gupta reports the following financial interests or relationships: Alcon Laboratories, Allergan, Inc., Andrews Institute, GENENTECH, IRIS, Novartis, Alcon Pharmaceuticals, Regeneron Pharmaceuticals, Retina Specialty Institute, Roche Diagnostics, Spark Therapeutics, USRetina, also outside of the submitted work. A Ortiz, A. Trivedi, J. Desbiens, M. Blazes, C. Robinson, R. Dodhia, W. Conrad, and J. Lavista declare no competing interests.